Cargando…

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer

With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Shengxiu, Wang, Liang, Sun, Yan, Du, Huakun, Yu, Xiaomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616240/ https://www.ncbi.nlm.nih.gov/pubmed/37915573 http://dx.doi.org/10.3389/fimmu.2023.1270828

Ejemplares similares

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
por: Zhao, Qing, et al.
Publicado: (2021)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
por: Sammarco, Enrico, et al.
Publicado: (2023)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Successful immune checkpoint inhibitor‐based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report
por: Yao, Yanhong, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022)

Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
por: Miao, Jing, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma
por: Ratanasrimetha, Praveen, et al.
Publicado: (2022)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study
por: Xu, Ziyi, et al.
Publicado: (2022)

A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
por: Yu, Eun-mi, et al.
Publicado: (2021)

Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor‐related myocarditis and myositis: rechallenge?
por: Rossi, Valentina A., et al.
Publicado: (2023)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yan, Yi-Dan, et al.
Publicado: (2021)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
por: Zarrabi, Kevin, et al.
Publicado: (2021)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers
por: Li, Ye, et al.
Publicado: (2021)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
por: Hu, Xiangxiao, et al.
Publicado: (2023)

Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report
por: Zarrabi, Maiah, et al.
Publicado: (2023)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma
por: Lin, Enyu, et al.
Publicado: (2021)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
Publicado: (2021)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
por: Ladouceur, Alexandra, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k9klq2gdekpsqa9pon528i1lon